Quarterly ResultMay 11, 2026, 07:36 AM
Bicara Therapeutics Q1 Net Loss $56.2M; Cash $539.8M
AI Summary
Bicara Therapeutics reported its first quarter 2026 financial results, with a net loss of $56.2 million, up from $36.8 million in Q1 2025, driven by increased R&D and G&A expenses. The company significantly bolstered its cash position to $539.8 million, including $161.8 million from a public offering, extending its cash runway into the first half of 2029. Bicara also announced plans to initiate a new randomized clinical study for ficerafusp alfa in Q3 2026 and made key executive appointments, including a new Chief Medical Officer and Chief Commercial Officer.
Key Highlights
- Cash, cash equivalents, and marketable securities increased to $539.8M as of March 31, 2026, from $414.8M in Q4 2025.
- Received $161.8M in net proceeds from an oversubscribed public offering in Q1 2026.
- Research and development expenses rose to $47.5M in Q1 2026 from $34.3M in Q1 2025.
- General and administrative expenses increased to $12.7M in Q1 2026 from $7.5M in Q1 2025.
- Net loss totaled $56.2M for Q1 2026, compared to $36.8M for Q1 2025.
- Net loss per share was $(0.93) for Q1 2026, compared to $(0.68) for Q1 2025.
- Expected cash runway into the first half of 2029.
- Initiation of a new randomized clinical study for ficerafusp alfa in 1L R/M HPV-negative HNSCC expected in Q3 2026.